A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. This type of pill is called "Bruton Tyrosine Kinase Inhibitor" or BTKi. Another treatment for CLL/SLL is a different pill called venetoclax. The purpose of this study is to compare continuing the current treatment with BTKi alone, as long as it is working, to another arm of treatment which adds venetoclax to the current treatment (BTKi), for one year. After one year, both pills in this arm of treatment

Trial Details

NCT ID
NCT06520098
Phase
PHASE2
Sponsor
VA Office of Research and Development
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Venetoclax
  • Ibrutinib, Acalabrutinib, Zanubrutinib
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Kansas City, Missouri, United States|39.09973,-94.57857
  • Durham, North Carolina, United States|35.99403,-78.89862
  • Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

  • Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) diagnosis
  • Patients must have been diagnosed with CLL (\> 5000 B-cells per microliter of peripheral blood at any point during the course of their disease) or …
  • Prior treatment
  • Patients must be currently receiving CLL/SLL directed therapy with a BTKi (i.e., ibrutinib, acalabrutinib, zanubrutinib) for at least six months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →